Lonza launches double-blinded capsules for trials

By Jenni Spinner contact

- Last updated on GMT

(Image: Lonza)
(Image: Lonza)

Related tags: Capsules, Clinical trials, Lonza

The company’s Capsugel DBcaps double-blinded capsules are designed to over-encapsulate drugs during clinical phases opaquely and securely.

Capsugel DBcaps are designed to cover drugs during clinical trials, with a high degree of visual coverage and visual obstruction. They come in a range of sizes and colors, enabling them to be used in a variety of pharmaceutical products in different shapes and formats.

Lonza product manager Julien Lamps told Outsourcing-Pharma that the product is designed to overcome some of the difficulties associated with blinded trials.

The main challenge in blinded clinical trials is to make sure that bias is avoided, meaning the enrolled patients and their care-givers shall not be able to distinguish one blinded form (the original or the placebo) from the one being tested, within and between the groups,” he explained. “Historically, this could have been achieved by adulterating the original form labelling, markings, or shapes but this raised then the question of the applicability of the study versus the effective use and mode of action for the original drug​.”

The Capsugel DBcaps feature a tamper-evident design to enable testing without bias. According to Lamps, the broad size and color range means the products are suitable for over0encapsulation of more than 90% of marketed solid oral dosage forms.

The double layer design, with cap over body, reportedly makes the product extremely difficult to open. Two polymers are available: gelatin, and HPMC; both are designed to be readily set to an existing range of small-to-mid-size filling machines, what accelerates speed to clinic.

Lamps added that by offering a standard gelatin and HPMC version, the Capsugel DBcaps line is made suitable for use with multiple formulation properties. Also, the relatively short length is intended to make it easy for patients to swallow.

According to Stephen Rode, Lonza business development manager, said the products enable users to comply with necessary blinding requirements.

During clinical trials it is imperative that sponsor companies and contract research companies alike can have peace of mind that they are complying sufficiently with blinding regulations to ensure a smooth journey to market​,” he said. “By combining anti-tampering measures with a flexible and robust product, we have been able to develop a solution that will meet the needs of our customers globally​.”

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars